Investors who have followed med-tech for a long time probably knew that this day was coming -- highly-valued MAKO Surgical (MAKO)
disappointed the Street with its quarterly results, and the
consequences in the market are going to be severe. Only zealots believed
that MAKO would grow with no interruptions or stumbles, and while the
valuation is still demanding, this looks like a potential opportunity
for aggressive investors.
Please continue here:
MAKO Surgical Hooked, But Not Gutted
No comments:
Post a Comment